TaqIB polymorphism in the cholesteryl ester transfer protein (CETP) gene influences lipid responses to the consumption of kiwifruit in hypercholesterolaemic men

Cheryl S. Gammon[1]*, Anne M. Minihane[2], Rozanne Kruger[1], Cathryn A. Conlon[1], Pamela R. von Hurst[1], Beatrix Jones[3] and Welma Stonehouse[1]

[1]*Institute of Food, Nutrition and Human Health, Massey University Albany, Albany Campus, Private Bag 102904 Auckland 0745, New Zealand*
[2]*Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK*
[3]*Institute of Information and Mathematical Sciences, Massey University Albany, Auckland, New Zealand*

Abstract

Fruit and vegetables are key elements of a cardioprotective diet, but benefits on plasma lipids, especially HDL-cholesterol (HDL-C), are inconsistent both within and between studies. In the present study, we investigated whether four selected HDL-C-related polymorphisms (cholesteryl ester transfer protein (CETP) Taq1B, APOA1 − 75G/A, hepatic lipase (LIPC) − 514C → T, and endothelial lipase (LIPG) I24582) modulate the plasma lipid response to a kiwifruit intervention. This is a retrospective analysis of data collected during a 12-week randomised controlled cross-over trial. A total of eighty-five hypercholesterolaemic men completed a 4-week healthy diet run-in period before being randomised to one of two 4-week intervention sequences of two green kiwifruit/d plus healthy diet (kiwifruit intervention) or healthy diet alone (control intervention). The measurement of anthropometric parameters and collection of fasting blood samples were carried out at baseline 1 and after the run-in (baseline 2) and intervention periods. At baseline 2, B1/B1 homozygotes of the CETP Taq1B gene had significantly higher total cholesterol:HDL-C, TAG:HDL-C, and apoB:apoA1 ratios and small-dense LDL concentrations than B2 carriers. A significant CETP Taq1B genotype × intervention interaction was observed for the TAG:HDL-C ratio ($P=0.03$). B1/B1 homozygotes had a significantly lower TAG:HDL-C (− 0.23 (sd 0.58) mmol/l; $P=0.03$) ratio after the kiwifruit intervention than after the control intervention, whereas the ratio of B2 carriers was not affected. The lipid response was not affected by other gene polymorphisms. In conclusion, the significant decrease in the TAG:HDL-C ratio in B1/B1 homozygotes suggests that regular inclusion of green kiwifruit as part of a healthy diet may improve the lipid profiles of hypercholesterolaemic men with this genotype.

Key words: Kiwifruit: *CETP* gene polymorphism: Diet–gene interactions: CVD risk

CVD is the leading cause of death globally[1]. Plasma HDL-cholesterol (HDL-C) concentrations are inversely associated with CVD risk and should be considered alongside LDL-cholesterol in the management of dyslipidaemic individuals[2,3]. Low HDL-C concentrations may reflect disturbances in TAG metabolism[2]. In conjunction with increased concentrations of TAG and small-dense LDL (sLDL) particles, they form the lipid triad or 'atherogenic lipoprotein phenotype' that is associated with obesity and insulin resistance (IR), the prevalence and subsequent contribution to CVD risk of which are steadily increasing[4]. Therefore, an understanding of the determinants of HDL-C concentrations is timely. Considerable variability in HDL-C concentrations exists within population groups[3,5]. Heritability estimates for

HDL-C concentrations range between 40 and 60 %. In addition, a range of environmental and metabolic factors, including TAG concentrations, waist circumference, high-sensitivity C-reactive protein concentrations, IR, alcohol consumption and smoking, have been shown to be associated with HDL-C concentrations[3,5–7].

Fruit and vegetables have long been identified as key elements of a cardioprotective diet. Yet, beyond the cholesterol-lowering properties of dietary fibres, conclusive benefits in relation to blood lipids remain largely unresolved. There are inconsistent findings, for example, as to the beneficial effects of flavonoid-rich fruit consumption on HDL-C concentrations[8,9]. Genetics, for example, differences in the prevalence of key gene variants, are likely to contribute to

---

Abbreviations: CETP, cholesteryl ester transfer protein; HDL-C, HDL-cholesterol; IR, insulin resistance; sLDL, small-dense LDL; TC, total cholesterol.

* **Corresponding author:** C. S. Gammon, fax +64 9 443 9640, email c.gammon@massey.ac.nz

some of the variability in responses between populations. To our knowledge, however, no studies have investigated the variability in responsiveness of blood lipids to an intervention involving fruit.

In 2010, we conducted a randomised controlled trial in hypercholesterolaemic men, in which we assessed the impact of consuming two green kiwifruit a day alongside a healthy diet on plasma lipids. The primary results of this trial indicated that the consumption of two green kiwifruit every day for 4 weeks had favourable effects on plasma HDL-C concentrations and the total cholesterol (TC):HDL-C ratio compared with the consumption of a healthy control diet alone[10].

Based on the primary results, one of the secondary objectives of the above-mentioned trial was to select gene polymorphisms related to lipid metabolism that could explain the heterogeneity in response observed. For the present study, we selected four SNP related to HDL metabolism, and given the sample size, we focused on common variants with more than 20% minor allele frequencies. The SNP chosen were the cholesteryl ester transfer protein (*CETP*) Taq1B, *APOA1* −75G/A, hepatic lipase (*LIPC*) −514C → T, and endothelial lipase (*LIPG*) I24582 (T+2864C/In8) variants.

CETP TaqIB is one of the most widely studied polymorphisms[11], and substantial evidence from meta-analyses shows an association with HDL-C concentrations[12,13]. Evidence is more limited for the other three SNP, but all have been reported to be associated with either HDL-C concentrations[14–17] or related factors[18–20].

Therefore, the aim of the present study was to assess the effects of these selected HDL-C-related polymorphisms on the plasma lipid response to a kiwifruit intervention.

Subjects and methods

Subjects and study design

Data for the analyses reported herein were obtained as part of an 8-week randomised controlled cross-over trial conducted between May and September 2010. The details of study participant recruitment, flow diagram, participants and protocol have been described previously[10]. Briefly, eighty-seven hypercholesterolaemic men with a LDL-cholesterol concentration >3·0 mmol/l and a plasma TAG concentration <3·0 mmol/l but otherwise who were healthy, non-smokers and not taking any cholesterol-lowering medication were recruited from the Auckland region in New Zealand. The study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Massey University Human Ethics Committee: Southern A 09/76. Written informed consent was obtained from all the subjects. The trial was registered with the Australian New Zealand Clinical Trials Registry (no. ACTRN12610000213044, http://www.ANZCTR.org.au).

The measurement of anthropometric parameters (height, waist circumference, weight and percentage body fat) and collection of blood samples for lipid analyses were carried out during the first visit (baseline 1) to the Massey University Human Nutrition Research Unit. The subjects had to complete a 3 d food record before attending a nutrition consultation with a nutritionist, during which details of the healthy diet that the subjects were required to follow for the 12 weeks of the study were outlined. The healthy diet was based on the Heart Foundation of New Zealand's '9 steps to Eating for a Healthy Heart' and was also used to make recommendations to improve their current dietary habits (Gammon *et al.*[10], Supplementary table (available online)) and included the requirement that they consume at least two servings of fruit (other than kiwifruit) per d. The nine steps are a series of guidelines to encourage individuals to make healthier choices focused on heart health, such as incorporating fruit and/or vegetables in every meal, choosing whole-grain breads and cereals instead of white and low-fibre varieties, and reducing salt, saturated fat and alcohol intakes. After completing their 4-week healthy diet run-in period, the subjects returned to the research unit and were randomly assigned, using computer-generated random numbers (http://www.randomization. com), to one of two 4-week intervention sequences: healthy diet alone (control intervention) or replacement of two of their normal fruit servings with two Zespri® Green kiwifruit (*Actinidia deliciosa* var. Hayward) per d (average weight without skin 176 g/d, which is approximately equivalent to 2 × 80 g standard fruit portions) plus a healthy diet (kiwifruit intervention). The collection of additional blood samples and measurement of anthropometric parameters and blood pressure were carried out, and a 24 h food record was completed by a nutritionist during this visit (baseline 2) and at the end of each intervention period, as detailed in Gammon *et al.*[10]. The subjects were requested to maintain their normal daily routine (including physical activity) for the duration of the study, and compliance was monitored by weekly self-completed diaries.

Laboratory measurements

Venous blood samples were collected into vacutainers buffered with EDTA or heparin or without an anticoagulant after an 8 h fast. Once processed, aliquots were stored at −80°C for analysis in one batch at the end of the study. Buffy coat aliquots were stored in LoBind DNA-free Eppendorf tubes (Eppendorf). Plasma lipid, serum apo, plasma glucose and insulin, and serum high-sensitivity C-reactive protein analyses were conducted by Canterbury Health Laboratories, Christchurch, New Zealand (IANZ ISO 15 189)[10]. SNP determination and sLDL analysis were conducted at the Biomedical Research Centre, University of East Anglia, Norwich, UK. The homeostasis model assessment 2 model was used to calculate IR, based on fasting insulin and glucose concentrations[21].

All the subjects (excluding one subject who requested not to be included in any gene analysis) were directly genotyped for four selected polymorphic sites: *CETP Taq1B* (rs708272); *APOA1* −75G/A (rs670); *LIPC* −514C → T (rs1800588); *LIPG* I24582 (T + 2864C/In8) (rs6507931). Genomic DNA was isolated from the buffy coat samples using the QIAamp DNA Mini Blood Kit (catalogue no. 51 104, QIAGEN Limited).

Table 1. Positions and genotypic distributions of the selected SNP and HDL-cholesterol (HDL-C) concentrations in the study population at baseline
(Mean values and standard deviations; geometric means and 95 % confidence intervals)

Genes	SNP ID	Chromosome	Location	Genotypes	n	%	HDL-C (mmol/l)*	Mean	SD	P
CETP Taq1B	rs708272	16	Intron	*AA (B2/B2)*	16	19·5	*B2 v. B1/B1* carriers	1·41	0·32	
				GA (B1/B2)	35	42·7		1·31	0·34	
				GG (B1/B1)	31	37·8				0·18
								Geometric mean	95 % CI	
APOA1 − 75G/A	rs670	11	Promoter	*AA*	5	6·1	*A v. G/G* carriers	1·29	1·20, 1·38	
				GA	30	36·6		1·38	1·29, 1·48	
				GG	47	57·3				0·15
LIPC 514C → T	rs1800588	15	Intergenic/ unknown	*CC*	48	58·5	*C/C v. T* carriers	1·35	1·27, 1·44	
				CT	27	32·9		1·32	1·22, 1·44	
				TT	7	8·5				0·65
LIPG I24582 (T + 2864C/In8)	rs6507931	18	Intron	*CC*	18	21·4	*C v. T/T* carriers	1·33	1·26, 1·40	
				CT	40	47·6		1·39	1·25, 1·53	
				TT	26	31·0				0·41

ID, identification; *CETP*, cholesteryl ester transfer protein; *LIPC*, hepatic lipase; *LIPG*, endothelial lipase.
* Mean values were significantly different between the genotype groups at baseline 1 (minor allele carriers *v.* major allele homozygotes) ($P < 0.05$; independent Student's *t* test).

Statistical analyses

A power calculation was carried out to establish the sample size for the primary study, and it was based on detecting a difference of 0·5 mmol/l in TC and LDL-cholesterol concentrations between the interventions and on the prevalence of apo *E4* allele carriers[10]. The sample sizes of 51 and 31 in the *Taq1B B2* carrier and *B1/B1* groups, respectively, retrospectively provided 98 % power in the *B2* carrier group and 87 % power in the *B1/B1* group to detect a mean difference of 0·24 mmol/l in the TC:HDL-C ratio at an α-level of 0·05. This was based on the significant difference in the TC:HDL-C ratio of *B1/B1* homozygotes during the kiwifruit and control intervention periods. This difference was related to about a 12 % reduction in CVD risk[22]. Additionally, the sample size provided 70 % power to detect a genotype × treatment interaction for the TC:HDL-C ratio.

Statistical analyses were carried out using IBM SPSS statistics version 20 (IBM Corporation). Normal distributions were tested using the Kolmogorov–Smirnov, Shapiro–Wilk tests and normality plots. Non-normally distributed data were transformed into approximately normal distributions, if possible, by logarithmic transformations. Normally distributed data are expressed as means and standard deviations or, when reporting inter-group differences, as mean difference with their standard errors. Non-normally distributed data are expressed as geometric means (95 % CI) if log-transformed (Table 1) or medians (25th and 75th percentiles) (Table 2).

The data were examined for any interaction effects due to the sequence of interventions (kiwifruit followed by control and vice versa) using a two-way ANOVA. No interaction was observed, and so data collected during the two intervention periods were combined.

Multivariate ANOVA was used as an initial screen to investigate differences in the multivariate patterns of lipid variables between the genotype groups (major allele homozygotes *v.* minor allele carriers) to reduce the likelihood of chance findings from multiple comparisons.

Significant effects of *CETP Taq1B* on the multivariate pattern of lipid responses were observed, and this observation was

Table 2. Baseline characteristics of the subjects by cholesteryl ester transfer protein (*CETP*) *Taq1B* genotype group

(Mean values and standard deviations at baseline 1, unless otherwise indicated; median values and 25th and 75th quartiles)

	CETP Taq1B				
	B2 carriers (n 51)		*B1/B1* homozygotes (n 31)		
Variables	Mean	SD	Mean	SD	P*
Age (years)	47	10	50	9	0·09
Height (m)	1·78	0·06	1·77	0·06	0·63
Weight (kg)	87·5	15·2	85·0	17·6	0·50
BMI (kg/m^2)	27·6	3·7	27·0	4·2	0·52
Waist circumference (cm)	94·0	10·4	92·3	9·9	0·46
% Body fat	27·3	7·3	28·0	8·2	0·71
SBP (mmHg)†	123	10	122	10	0·76
DBP (mmHg)†	71	9	71	9	0·70
HOMA2-IR†					0·76
Median	1·03		0·96		
25th–75th quartile	0·64–1·47		0·60–1·72		
hs-CRP (mg/l)†					0·70
Median	0·98		1·06		
25th–75th quartile	0·61–2·16		0·52–1·83		

SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA2-IR, homeostasis model assessment 2 model for insulin resistance; hs-CRP, high-sensitivity C-reactive protein.
* Values were significantly different between *B2* carriers and *B1/B1* homozygotes ($P < 0.05$; independent Student's *t* test and Mann–Whitney test).
† Values obtained at baseline 2.

Applied Biosystems 7500 Fast Real-Time PCR System (software version 2.0.5; Applied Biosystems) and TaqMan® SNP genotyping assays (Applied Biosystems) were used to determine the allelic discrimination of the selected gene variants.

backed by an assessment of assumptions and univariate patterns. Therefore, further analysis of this genotype was conducted. Repeated-measures ANOVA was used to examine genotype × treatment interactions. For ANOVA interactions where $P < 0.05$, a stratified analysis was carried out. Data were stratified by genotype group, and within-group comparisons between baseline 2 and end of the intervention periods (control and green kiwifruit interventions separately) and between the control intervention period and the kiwifruit intervention period for changes in each univariate lipid measure were made using dependent Student's *t* tests. Between-group comparisons for other variables were made using independent Student's *t* tests or Mann–Whitney test for non-normal data. Differences were considered significant at $P < 0.05$.

Results

As has been reported previously, eighty-five subjects completed the 12-week trial[10]. Genotyping was completed for eighty-four subjects, although alleles for two subjects for three of the SNP could not be determined. Table 1 reports the positions and genotypic distributions for the four selected SNP. HDL-C concentrations at baseline 1, by genotype group (minor allele carriers *v.* major allele homozygotes), are also reported in Table 1. There was no significant difference in HDL-C concentrations between minor allele carriers and major allele homozygotes for any SNP at baseline 1.

Based on the results of the initial statistical screening using multivariate ANOVA, the *CETP Taq1B* SNP was found to affect the lipid profile at baseline 2 ($F(10,71) = 3.561$; $P = 0.001$). No significant results were obtained for any other SNP; therefore, further analysis was carried out only for the *CETP Taq1B* SNP.

Baseline characteristics of the subjects by cholesteryl ester transfer protein Taq1B genotype group

The baseline characteristics of the subjects stratified by *CETP Taq1B* genotype group are summarised in Table 2. There were no significant differences between the two groups for any anthropometric parameter, blood pressure, homeostasis model assessment 2-IR or high-sensitivity C-reactive protein concentrations.

Dietary intakes during the interventions by cholesteryl ester transfer protein Taq1B genotype group

Dietary intakes according to genotype group are summarised in Table 3. There was a small, but significant difference in energy intake between kiwifruit and control intervention periods in both groups. No significant differences in macronutrient intake were seen between kiwifruit and control intervention periods for either group. In both the groups, significantly higher intakes were observed for vitamins C and E during the kiwifruit intervention period than during the control intervention period.

Table 3. Dietary intakes during the interventions by cholesteryl ester transfer protein *Taq1B* genotype group

(Mean values and standard deviations; median values and 25th and 75th quartiles, *n* 51 *B2* carriers and *n* 31 *B1/B1* homozygotes)

Variables	Baseline 2		End-Kiwifruit		End-Control		P*
	Mean	SD	Mean	SD	Mean	SD	
Energy (kJ)							
B2 carriers	9261	2705	9759	2696	8987	2386	0·04
B1/B1 homozygotes	8774	2052	9226	1892	8211	1813	0·01
Fat (% energy)							
B2 carriers	27·7	7·00	28·3	8·34	26·9	7·70	0·32
B1/B1 homozygotes	24·3	5·91	29·6†	5·88	27·3	6·87	0·14
Protein (% energy)							
B2 carriers	19·9	4·98	19·5	4·94	19·9	4·50	0·61
B1/B1 homozygotes	19·2	5·95	20·0	4·17	19·9	4·84	0·92
Carbohydrate (% energy)							
B2 carriers	48·5	8·64	49·5	9·20	50·0	9·71	0·69
B1/B1 homozygotes	53·1	9·83	47·4†	6·18	49·6†	8·43	0·22
Vitamin E (mg)							
B2 carriers	9·58	3·51	13·4†	4·29	9·81	4·24	<0·001
B1/B1 homozygotes	11·2	6·17	14·2†	4·66	8·03†	3·47	<0·001
Vitamin C (mg)							
B2 carriers							0·05
Median	122		296†		251†		
25th–75th quartile	70·0–160		251–336		130–321		
B1/B1 homozygotes							<0·001
Median	128		272†		182†		
25th–75th quartile	80·7–152		226–336		89–282		

End-Kiwifruit, end of the kiwifruit intervention period; End-Control, end of the control intervention period.
* Values were significantly different between the green kiwifruit and control interventions ($P < 0.05$; dependent Student's *t* test or Wilcoxon signed-rank test).
† Mean values were significantly different from baseline 2 to the end of the intervention period ($P < 0.05$; dependent Student's *t* test or Wilcoxon signed-rank test).

When fruit servings per d were analysed by genotype, no significant differences were observed between the two groups for any period. At baseline 1, the median intake for both groups was 1·33 servings per d (below recommendations); this increased to two servings at baseline 2 and three servings during the two intervention periods.

Effects of diet run-in period and interventions on body weight by cholesteryl ester transfer protein Taq1B genotype group

During the 4-week healthy diet run-in period, there were small, but significant decreases in weight (mean difference −0·39 (SD 1·33) kg, $P=0·04$) and BMI (mean difference −0·12 (SD 0·41) kg/m^2, $P=0·05$) in *B2* carriers and in percentage body fat (mean difference −0·60 (SD 1·35), $P=0·02$) in *B1/B1* homozygotes. From the end of this period (baseline 2) to the end of the 8-week intervention period, there were no changes in body weight in either group regardless of the intervention received by the groups (green kiwifruit or control) (Supplementary table, available online).

Effects of interventions on lipid concentrations by cholesteryl ester transfer protein Taq1B genotype group

The effects of interventions on plasma lipid concentrations by *CETP Taq1B* genotype group are summarised in Table 4. At baseline 2, *B2* carriers had significantly lower TC:HDL-C ratio (mean difference −0·39 (SE 0·19) mmol/l, $P=0·05$), TAG:HDL-C ratio (mean difference −0·31 (SE 0·15) mmol/l, $P=0·05$), and apoB1:apoA1 ratio (mean difference −0·10 (SE 0·05) g/l, $P=0·04$) and sLDL concentrations (mean difference −0·24 (SE 0·12) mmol/l, $P=0·05$) than *B1* homozygotes. The differences between *B2* carriers and *B1* homozygotes with regard to HDL-C and apoA1 concentrations were 0·14

(SE 0·07) mmol/l, $P=0·07$, and −0·11 (SE 0·05) g/l, $P=0·06$, respectively.

There was no genotype × treatment interaction for HDL-C concentrations. The kiwifruit intervention resulted in greater HDL-C concentrations than the control intervention in both the genotype groups. The mean difference between kiwifruit and control intervention periods for HDL-C was 0·06 (SD 0·10) mmol/l, $P=0·002$, for *B1/B1* homozygotes and 0·05 (SD 0·15) mmol/l, $P=0·03$, for *B2* carriers, with this group (B2 carriers) during the control intervention period having a significant decrease from baseline −0·05 (SD 0·15) mmol/l, $P=0·02$.

There was a significant genotype × treatment interaction for the TAG:HDL-C ratio ($P=0·03$). On stratification for this variable, the two genotype groups were found to differ in response to the interventions, with *B1/B1* homozygotes responding favourably, with significant improvements being observed during the kiwifruit intervention period than during the control intervention period for the TAG:HDL ratio, −0·23 (SD 0·58) mmol/l, $P=0·03$. There were no significant treatment differences in *B2* carriers. Since significant ($P<0·05$) genotype × treatment interactions were not observed for any of the other lipid variables, results of stratified analysis for these are not reported.

Discussion

To our knowledge, this is the first study to report a possible association between a polymorphism in the *CETP* gene and plasma lipid response to a fruit intervention. Since the results are based on one SNP and a relatively small cohort, the findings should be seen as explorative and will need to be confirmed in future research in a larger sample.

The genotype frequencies for all the four SNP investigated in the present study were in line with those reported by other studies in the literature[12,14–17,19,23–25]. However, there

Table 4. Changes in plasma lipid and apolipoprotein concentrations during the two intervention periods by cholesteryl ester transfer protein *Taq1B* genotype group‖

(Mean values and standard deviations)

	B2 carriers (*n* 51)						*B1/B1* homozygotes (*n* 31)						Between groups *P*‡
	Baseline 2		Kiwifruit change		Control change		Baseline 2		Kiwifruit change		Control change		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
TC (mmol/l)	6·17	0·97	0·05	0·76	0·008	0·78	5·99	0·84	0·06	0·69	0·09	0·59	0·59
LDL-C (mmol/l)	4·00	0·74	−0·002	0·59	0·03	0·65	3·88	0·73	0·07	0·54	0·09	0·48	0·93
HDL-C (mmol/l)	1·46	0·31	−0·006	0·18	−0·05*	0·15	1·33	0·35	0·05	0·16	−0·01	0·13	0·75
TAG (mmol/l)	1·57	0·54	0·17	0·82	0·06	0·46	1·71	0·76	−0·10	0·60	0·07	0·59	0·08
TC:HDL-C ratio	4·31†	0·60	0·07	0·40	0·17*	0·37	4·70†	0·96	−0·12	0·39	0·12	0·44	0·14
TAG:HDL-C ratio	1·12†	0·44	0·15	0·66	0·08	0·35	1·43†	0·79	−0·14	0·51	0·09	0·56	0·03
P§			0·43						0·03				
ApoA1 (g/l)	1·42	0·23	0·02	0·13	−0·003	0·12	1·31	0·26	0·05	0·14	0·03	0·13	0·85
ApoB (g/l)	1·10	0·21	0·005	0·13	0·001	0·14	1·13	0·22	0·01	0·13	0·03	0·11	0·52
ApoB:apoA1 ratio	0·79†	0·16	−0·004	0·09	0·009	0·08	0·89†	0·24	−0·02	0·07	0·004	0·08	0·42
sLDL (mmol/l)	1·18†	0·50	0·04	0·38	0·03	0·37	1·41†	0·55	−0·03	0·46	0·03	0·42	0·47

TC, total cholesterol; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; sLDL, small-dense LDL.

* Mean values were significantly different from baseline 2 to the end of the intervention period ($P<0·05$; dependent Student's *t* test).

† Mean values were significantly different between *B2* carriers and *B1/B1* homozygotes ($P<0·05$; independent Student's *t* test).

‡ Values were significantly different between the genotype groups, treatment × gene interaction ($P<0·05$; repeated-measures ANOVA).

§ Values were significantly different between the kiwifruit and control interventions ($P<0·05$; dependent Student's *t* test). Only *P* values for variables with an ANOVA interaction ($P<0·05$) are reported.

‖ Subjects followed a cross-over design protocol during the two intervention periods.

was a tendency towards a greater percentage of minor allele carriers for *APOA1* −75G/A (42·7 *v.* 28–29·6%)[23,25] in the participants of the present study.

The *CETP Taq1B* genotype significantly modulated the TAG:HDL-C ratio in response to the kiwifruit intervention. Favourable effects of consuming two green kiwifruit a day against the background of a healthy diet were observed on the plasma TAG:HDL-C ratio, but only in *B1/B1* homozygotes of the *CETP Taq1B* genotype. The HDL-C response was not modulated by the *CETP Taq1B* genotype, since improvements were observed in both the genotype groups. Although no genotype interactions were observed for the TC:HDL-C ratio or TAG concentrations, the lack of observed effects may have been due to insufficient power (70% power to observe an interaction effect on the TC:HDL-C ratio), as there were trends of greater improvement in these variables in *B1/B1* homozygotes, but not in *B2* carriers.

The most established function of CETP is the mediation of the transfer of neutral lipids, cholesteryl esters (mainly from HDL-C) and TAG (found in TAG-rich lipoproteins, VLDL and chylomicrons) between plasma lipoproteins[26,27]. Elevated CETP activity results in enhanced TAG enrichment of both HDL and/or LDL, which are more readily remodelled by LIPC into smaller particles. This consequently leads to a decrease in plasma HDL-C and apoA1 concentrations as a result of increased removal of these HDL remnants from circulation by renal clearance and/or the hepatic holo-receptor and an increase in the number of atherogenic sLDL particles[27,28].

The *TaqIB* polymorphism of the *CETP* gene is due to a base change from G to A at position 277 in intron 1. It is not readily apparent as to how this base change can modulate CETP expression. However, it has been suggested that while the SNP is not itself functional, it may act as a marker due to its linkage disequilibrium with a functional variant[11,29]. Moderate inhibition of CETP activity and higher HDL-C and apoA1 and lower TAG concentrations have been observed in *B2* carriers than in *B1/B1* homozygotes[13]. Conversely, *B1/B1* homozygotes tend to have a more atherogenic lipoprotein profile[30].

In the present study, minor allele frequency for *CETP Taq1B* was 41%, which compares closely with the value of 42% calculated in healthy white individuals in a meta-analysis[13]. *B2* carriers tended to have higher HDL-C and apoA1 and lower TAG concentrations than *B1/B1* homozygotes at baseline 2, but the differences were not significant, possibly as a result of a lack of power. However, at baseline 2, TC:HDL-C, TAG:HDL-C and apoB:apoA1 ratios and sLDL concentrations were significantly lower in *B2* carriers than in *B1/B1* homozygotes. Overall, this is suggestive of a better CVD risk profile for *B2* carriers, in line with the literature[13].

The current increase in obesity rates and associated deleterious effects on lipid and lipoprotein metabolism, independent of LDL-cholesterol concentrations, have led to much research being focused on strategies to address these other lipoprotein abnormalities. Recent research suggests that lipid and lipoprotein ratios have a greater predictive value than isolated parameters, with regard to CVD risk, as they more accurately capture overall lipoprotein metabolism[4,31]. The TAG:HDL-C ratio has been suggested as a surrogate marker for IR, describing altered lipid and carbohydrate metabolism[32]. Furthermore, the ratio is linked to the presence of atherogenic sLDL[33]. With improvements being observed in the TAG:HDL-C ratio, the results of the present study indicate that *B1/B1* homozygotes of the *CETP Taq1B* SNP (more than 30% of the population) could particularly benefit from the regular daily consumption of green kiwifruit. Although modest, the reduction in the TAG:HDL-C ratio, if confirmed, could be expected to translate into CVD risk reduction in this group.

Although we did not measure CETP mass or activity, we hypothesise that the variance in responses to the kiwifruit intervention between *B1/B1* homozygotes and *B2* carriers observed in the present study may be mediated in part by a differential impact of kiwifruit bioactives on CETP activity, with a greater inhibition in *B1/B1* homozygotes along with the net effect of increasing HDL-C and decreasing TAG concentrations. In a 6-week study in hamsters, the addition of apple polyphenols to a control diet has been found to lower CETP activity and result in higher HDL-C and lower TAG concentrations. The inhibition of CETP by apple polyphenols has also been confirmed *in vitro*[34]. Some of these apple polyphenols are also found in kiwifruit, with kiwifruit also containing a high percentage of additional unextractable (non-identified) phenolics[35–37].

A strength of the present study was the randomly controlled cross-over design, as this is considered to be the most robust statistically to identify inter-individual variability in dietary responses, as subjects serve as their own controls[38]. The SNP chosen were carefully considered with regard to factors such as the frequencies of the alleles and their relationship with HDL metabolism.

As a retrospective analysis, which is, therefore, exploratory by nature, the study does have some limitations. Importantly, mechanistic pathways could not be explored, including whether kiwifruit can inhibit CETP activity. The study was also conducted in a specific population group. Therefore, it will be important for future studies to not only confirm our findings, but also to test the effects in other populations, including women.

In conclusion, we report that the *Taq1B* polymorphism of the *CETP* gene could modulate the plasma lipid response to the consumption of green kiwifruit against an overall healthy diet background in hypercholesterolaemic males, with improvements in the TAG:HLD-C ratio of *B1/B1* homozygotes, a group at a higher risk of an atherogenic lipoprotein profile. Although moderate, if confirmed, these effects could be expected to translate into an overall reduction of CVD risk in *B1/B1* homozygotes and add to the accumulating evidence that this genotype may particularly benefit from targeted interventions.

These findings add to the body of evidence on diet–gene interactions, which may in future lead to a greater personalisation of dietary recommendations. However, this area of research is far more complex than first thought, and the challenge is to integrate multiple genetic, physiological and

environmental interactions into stratified recommendations that will afford maximum benefit to individuals[38,39].

Supplementary material

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S0007114513003437

Acknowledgements

References

1. WHO (2011) *Cardiovascular Diseases Fact Sheet* no. 317. Geneva: World Health Organization.

2. Vergeer M, Holleboom AG, Kastelein JJP, *et al.* (2010) The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? *J Lipid Res* **51**, 2058–2073.

3. Hansel B, Kontush A, Giral P, *et al.* (2006) One third of the variability in HDL-cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia: The Paris La Pitie Study. *Curr Med Res Opin* **22**, 1149–1160.

4. Musunuru K (2010) Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. *Lipids* **45**, 907–914.

5. Bove M, Cicero AFG, Manca M, *et al.* (2007) Sources of variability of plasma HDL-cholesterol levels. *Future Lipidol* **2**, 557–569.

6. Heller DA, de Faire U, Pedersen NL, *et al.* (1993) Genetic and environmental influences on serum lipid levels in twins. *N Engl J Med* **328**, 1150–1156.

7. Peloso GM, Demissie S, Collins D, *et al.* (2010) Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. *J Lipid Res* **51**, 3524–3532.

8. Chong MF, Macdonald R & Lovegrove JA (2010) Fruit polyphenols and CVD risk: a review of human intervention studies. *Br J Nutr* **104**, Suppl. 3, S28–S39.

9. Dauchet L, Amouyel P, Dallongeville J, *et al.* (2009) Fruits, vegetables and coronary heart disease. *Nat Rev Cardiol* **6**, 599–608.

10. Gammon CS, Kruger R, Minihane AM, *et al.* (2013) Kiwifruit consumption favourably affects plasma lipids in a randomised controlled trial in hypercholesterolaemic men. *Br J Nutr* **109**, 2208–2218.

11. de Grooth GJ, Klerkx AH, Stroes ES, *et al.* (2004) A review of CETP and its relation to atherosclerosis. *J Lipid Res* **45**, 1967–1974.

12. Boekholdt SM, Sacks FM, Jukema JW, *et al.* (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. *Circulation* **111**, 278–287.

13. Thompson A, Di Angelantonio E, Sarwar N., *et al.* (2008) Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. *JAMA* **299**, 2777–2788.

14. Mank-Seymour AR, Durham KL, Thompson JF, *et al.* (2004) Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels. *Biochim Biophys Acta* **1636**, 40–46.

15. Nettleton JA, Steffen LM, Ballantyne CM, *et al.* (2007) Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. *Atherosclerosis* **194**, e131–e140.

16. Ordovas JM, Corella D, Demissie S, *et al.* (2002) Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene–nutrient interaction in the Framingham Study. *Circulation* **106**, 2315–2321.

17. Zhang C, Lopez-Ridaura R, Rimm EB, *et al.* (2005) Interactions between the −514C->T polymorphism of the hepatic lipase gene and lifestyle factors in relation to HDL concentrations among US diabetic men. *Am J Clin Nutr* **81**, 1429–1435.

18. Juo SH, Wyszynski DF, Beaty TH, *et al.* (1999) Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: a meta-analysis. *Am J Med Genet* **82**, 235–241.

19. Ruano G, Seip RL, Windemuth A, *et al.* (2006) Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training. *Atherosclerosis* **185**, 65–69.

20. Souverein OW, Jukema JW, Boekholdt SM, *et al.* (2005) Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD. *Eur J Hum Genet* **13**, 445–451.

21. Wallace TM, Levy JC & Matthews DR (2004) Use and abuse of HOMA modeling. *Diabetes Care* **27**, 1487–1495.

22. Stampfer MJ, Sacks FM, Salvini S, *et al.* (1991) A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. *N Engl J Med* **325**, 373–381.

23. Do HQ, Nazih H, Luc G, *et al.* (2009) Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. *Metabolism* **58**, 283–289.

24. Smith CE, Arnett DK, Tsai MY, *et al.* (2009) Physical inactivity interacts with an endothelial lipase polymorphism to modulate high density lipoprotein cholesterol in the GOLDN study. *Atherosclerosis* **206**, 500–504.

25. Ordovas JM, Corella D, Cupples LA, *et al.* (2002) Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. *Am J Clin Nutr* **75**, 38–46.

26. Barter PJ, Brewer HB Jr, Chapman MJ, *et al.* (2003) Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. *Arterioscler Thromb Vasc Biol* **23**, 160–167.

27. Chapman MJ, Le Goff W, Guerin M, *et al.* (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. *Eur Heart J* **31**, 149–164.

28. Charles MA & Kane JP (2012) New molecular insights into CETP structure and function: a review. *J Lipid Res* **53**, 1451–1458.

29. Boekholdt SM & Thompson JF (2003) Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. *J Lipid Res* **44**, 1080–1093.

30. Dullaart RPF & Sluiter WJ (2008) Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. *Pharmacogenomics* **9**, 747–763.

31. Millan J, Pinto X, Munoz A, *et al.* (2009) Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. *Vasc Health Risk Manag* **5**, 757–765.

32. Cordero A, Andres E, Ordonez B, *et al.* (2009) Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. *Am J Cardiol* **104**, 1393–1397.

33. Miller M, Stone NJ, Ballantyne C, *et al.* (2011) Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* **123**, 2292–2333.

34. Lam CK, Zhang Z, Yu H, *et al.* (2008) Apple polyphenols inhibit plasma CETP activity and reduce the ratio of non-HDL to HDL cholesterol. *Mol Nutr Food Res* **52**, 950–958.

35. Fiorentino A, D'Abrosca B, Pacifico S, *et al.* (2009) Identification and assessment of antioxidant capacity of phytochemicals from kiwi fruits. *J Agric Food Chem* **57**, 4148–4155.

36. Latocha P, Krupa T, Wolosiak R, *et al.* (2010) Antioxidant activity and chemical difference in fruit of different *Actinidia* sp. *Int J Food Sci Nutr* **61**, 381–394.

37. Tarascou I, Souquet JM, Mazauric JP, *et al.* (2010) The hidden face of food phenolic composition. *Arch Biochem Biophys* **501**, 16–22.

38. Rideout TC (2011) Getting personal: considering variable interindividual responsiveness to dietary lipid-lowering therapies. *Curr Opin Lipidol* **22**, 37–42.

39. Minihane AM (2013) The genetic contribution to disease risk and variability in response to diet: where is the hidden heritability? *Proc Nutr Soc* **72**, 40–47.